<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pulmonary complications are frequently encountered in patients with <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The optimal therapeutic decision including open lung biopsy (OLB) for such patients is uncertain </plain></SENT>
<SENT sid="2" pm="."><plain>We herein examine the clinical impact of OLB on these patients </plain></SENT>
<SENT sid="3" pm="."><plain>Seven patients with progressively diffuse <z:hpo ids='HP_0002113'>pulmonary infiltrates</z:hpo> despite aggressive medical treatment were examined </plain></SENT>
<SENT sid="4" pm="."><plain>The underlying diseases, prior treatment for presumptive <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, the change in therapeutic approach after operation, and clinical outcome were reviewed retrospectively </plain></SENT>
<SENT sid="5" pm="."><plain>Diffuse <z:hpo ids='HP_0002113'>pulmonary infiltrates</z:hpo> were caused by <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in two patients and by noninfectious etiology such as <z:mp ids='MP_0010998'>alveolar proteinosis</z:mp>, idiopathic <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo>, leukemic involvement, and drug-induced alveolar damage in the others </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients who had serious underlying <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> such as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and T cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> died </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients with <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> survived </plain></SENT>
<SENT sid="8" pm="."><plain>In two of these three, change of therapeutic strategies after OLB was created for the survival </plain></SENT>
<SENT sid="9" pm="."><plain>OLB in patients with <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> may be useful in selected patients with a treatable <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic disease</z:e> who have treatable underlying causes of the pulmonary infiltrate </plain></SENT>
</text></document>